Interactive Dysautonomia Instrument

POTS Subtype Diagnostic Evaluator: Neuropathic vs. Hyperadrenergic vs. Hypovolemic

1. Why Identifying Your POTS Subtype Changes Everything

Postural Orthostatic Tachycardia Syndrome (POTS) is not a single disease; it is a clinical hemodynamic presentation driven by distinct underlying physiological mechanisms. Prescribing a standard POTS treatment without knowing the patient's subtype often leads to clinical failure: for instance, high-dose fludrocortisone or midodrine can precipitate dangerous hypertensive crises in Hyperadrenergic POTS, while beta-blockers without volume expansion can worsen dizziness in Hypovolemic POTS.

This interactive evaluator uses validated autonomic clinical markers—including orthostatic blood pressure deltas, plasma norepinephrine responses, sudomotor symptoms, and volume depletion indices—to determine your primary and secondary POTS phenotypes.

Diagnostic Assistant

POTS Phenotype Assessment Calculator

100% Client-Side Private
Primary Match: Neuropathic POTS with Secondary Hypovolemia Evidence-Based Phenotype

Neuropathic POTS (Peripheral Autonomic Denervation)

Your profile strongly aligns with Neuropathic POTS. In this phenotype, sympathetic adrenergic nerves innervating lower extremity blood vessels are partially damaged (confirmed in ~50% of patients via Small Fiber Neuropathy skin punch biopsy). When standing, blood pools rapidly in the mesenteric veins and calves, reducing venous return to the heart and forcing compensatory reflex tachycardia.

First-Line Pharmacological Matrix:
  • Pyridostigmine (Mestinon): 30–60 mg TID; enhances vagal tone and splanchnic vasoconstriction without raising heart rate.
  • Midodrine: 2.5–10 mg TID; selective alpha-1 adrenergic agonist to constrict pooled capacitance veins.
  • Fludrocortisone (Florinef): 0.1–0.2 mg daily; mineralocorticoid to expand intravascular plasma volume.
Non-Pharmacological Protocol:
  • Abdominal Compression: 3-panel medical elastic binder (20–30 mmHg) compresses the splanchnic reservoir.
  • High Sodium Hydration: 5,000–8,000 mg NaCl with 2.5–3L water using WHO Oral Rehydration Salts.
  • Counter-Maneuvers: Heel-to-toe pumps, leg crossing, and recumbent horizontal pacing.
View Full Clinical POTS Protocol →

2. Clinical Comparison of the Three Primary POTS Subtypes

Feature / Parameter Neuropathic POTS Hyperadrenergic POTS Hypovolemic POTS
Primary Mechanism Peripheral sympathetic denervation & SFN Central sympathetic hyper-drive (↑ Norepinephrine) Low absolute circulating plasma & erythrocyte volume
Standing Blood Pressure Normal or slight systolic drop Elevated (≥ 10 mmHg systolic increase) Narrow pulse pressure, drops if severe
Plasma Norepinephrine (Standing) Normal or low in lower limbs Markedly elevated (> 600 pg/mL) Mild compensatory elevation
Key Physical Signs Severe leg acrocyanosis (purple feet), cold skin Tremors, facial flushing, anxiety surges, palpitations Extreme unquenchable thirst, rapid urination, dry mucous membranes
Preferred First-Line Drugs Midodrine, Mestinon, Compression Clonidine, Guanfacine, Ivabradine, Beta-Blockers Fludrocortisone, High-dose Salt, Desmopressin, IV Saline